Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

By S. Nissen, E. Tuzcu, Paul-Henry Schoenhagen, T. Crowe, W. Sasiela, J. Tsai, J. Orazem, R. Magorien, C. O'shaughnessy, P. Ganz. New England Journal of Medicine, 2005

705 citations recorded by the source corpus.

Subfields: Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/b033bb34afc2e5fabcd63e1dd80c08fe9a05cbfe

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Epidemiology

1. P. Ridker
2. Peter Libby
3. N. Rifai
4. Christie M. Ballantyne
5. Nancy R. Cook
6. G. Hansson
7. L. Melvin
8. S. Grundy

In Surgery

1. P. Ridker
2. Peter Libby
3. N. Rifai
4. E. Tuzcu
5. Paul-Henry Schoenhagen
6. T. Crowe
7. Nancy R. Cook
8. G. Bradwin

Citations in the corpus

• C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. (2007, neutral): “…(Reversal of Atherosclerosis With Aggressive Lipid Lowering Therapy) trial that used intravascular ultrasound to measure disease progression over 18 months of statin therapy, individuals who achieved below median levels of both LDL and hsCRP achieved the greatest coronary atheroma regression (81).”
• Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. (2005, background): “With regard to high-sensitivity CRP, recent data suggest potential utility for this inflammatory biomarker as an adjunctive method to monitor statin efficacy not as a replacement for LDL-C.(34-36) The possible role of combined apolipoprotein and high-sensitivity CRP evaluation to monitor patients ta”
• Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. (2007, background): “More recently, reductions in levels of the inflammatory biomarker CRP in patients treated with statins have been associated with clinical benefits, including the slowing of disease progression and reduction in morbidity and mortality.(12,13) Epidemiological studies also show a strong relationship be”
• Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006, methodology): “Most atherosclerosis trialshavedemonstratedthat active lipid-modulating therapy,primarily using statin drugs, can reduce the rate of disease progression.(12-14,19) Two small, single-center trials have suggested that statins might induce regression, but methodological issues including small sample si”